Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.

Official Title

A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid Syndrome

Keywords

Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Neuroendocrine tumor, Paltusotine, CRN00808, Lanreotide, Octreotide, Somatostatin agonist, Neoplasms, Malignant Carcinoid Syndrome, Pancreatic Neoplasms, Syndrome, Diarrhea, Serotonin Syndrome, Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine

Eligibility

Locations

  • Crinetics Study Site
    Los Angeles California 90095 United States
  • Crinetics Study Site
    Los Angeles California 90048 United States
  • Crinetics Study Site
    Newport Beach California 92663 United States
  • Crinetics Study Site
    Stanford California 94305 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Crinetics Pharmaceuticals Inc.
ID
NCT05361668
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 36 people participating
Last Updated